This article summarizes the system for setting and controlling the prices of drugs for human consumption[1] and points out some observations made by the pharmaceutical sector to such system with regard to the possible reform of Executive Decree 400.
The purchase process, especially in large companies, has become a complex process in which it is necessary to give specific answers that are legally supported in the shortest possible amount of time.